Do any guidelines address stretching Ajovy dosing beyond 30 days?

The short version: no guideline in the retrieved evidence addresses stretching Ajovy beyond 30 days, but real-world data show quarterly dosing works as well as monthly for many patients.

The retrieved records cover efficacy, safety, and real-world use, but none is a professional guideline. The closest evidence is a 2025 real-world study of 165 patients that found no significant difference in migraine-day reduction between monthly 225 mg and quarterly 675 mg dosing over 24 months [2]. That study also found patients on quarterly dosing were far more likely to keep taking the drug: about 78 in 100 were still on it at 24 months versus about 47 in 100 on monthly dosing [2]. The drug's roughly 30-day half-life means a quarterly dose leaves very low blood levels in the third month, yet efficacy held [2].

The pivotal trials tested monthly and quarterly regimens and found both worked, with quarterly dosing reducing migraine days by about 3.4 days in episodic and 4.9 days in chronic migraine versus placebo [1]. The 2026 systematic review confirms efficacy but notes trials had short follow-up and homogeneous populations [3]. No retrieved record tests an interval between 30 and 90 days, so the specific question of a 60-day stretch has no direct evidence.

The evidence base is thin for this exact question. The manufacturer funded the pivotal trials [1]. No guideline, no dose-finding study for intermediate intervals, and no long-term safety data beyond 24 months appear in this retrieval [2][3].

My call: stretching to 60 days is plausible given quarterly data, but no guideline or trial directly supports it. Confidence: low.